Stellar Announces Chow and Brisson to New C-Level Posts

Stellar Biotechnologies, Inc. has announced that Herbert S. Chow, Ph.D. has been appointed to the position of Chief Technology Officer (CTO) and Catherine Brisson, Ph.D. has been appointed the position of Chief Pharmaceutical Officer (CPO) for the Company.

Stellar’s President & CEO, Frank Oakes said, “This is an important move for Stellar as it fills two key positions on senior management team with two extremely talented professionals with extensive experience in the science and technology surrounding KLH, and a deep understanding of our strategic pathway and product pipeline. I do not believe the Company could have found two more qualified candidates to meet the challenges of these two key positions and support the effective execution of the company’s plan over the next few years.”

New CPO, Catherine Brisson said, “I am very excited to be a part of this technology which perfectly fits the needs of the pharmaceutical industry. I feel confident that my commercial development expertise and strategic insight will contribute to Stellar’s immediate and future successes. I am pleased to be working in this new capacity with the first-class team of scientific, engineering, and business leaders that Stellar has assembled-all focused on tackling a challenging but critically important mission of advancing the innovative KLH therapeutic platform.”

New CTO, Herbert Chow said, “I am looking forward to working with the management team, our Board and Scientific Advisory Board to design and advance an innovative pipeline of KLH based vaccine candidates for the diagnosis and treatment of serious indications with a huge unmet medical need. I am excited to face the challenges ahead and to lead the development of the next generation of infectious disease and oncology vaccine solutions.”